108 results on '"Blau, Igor Wolfgang"'
Search Results
2. Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
3. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
4. Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years
5. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients
6. PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation
7. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype
8. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation
9. The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT
10. Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: A multi-centre observational study
11. Risk factors for Nocardia infection among allogeneic hematopoietic cell transplant recipients: A case-control study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation
12. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)
13. Influence of invasive aspergillosis during acute leukaemia treatment on survival after allogeneic stem cell transplantation: a prospective study of the EBMT Infectious Diseases Working Party
14. Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia
15. Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis
16. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial
17. Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post‐transplant cyclophosphamide versus conventional anti‐graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
18. Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core‐binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
19. Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)
20. Early bilirubinemia after allogeneic stem cell transplantation—an endothelial complication
21. Clinical outcome of older adults with acute myeloid Leukemia: An analysis of a large tertiary referral Center over two decades
22. Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT
23. FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
24. Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation
25. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
26. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
27. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients
28. Comparable CD8+ T‐cell responses to SARS‐CoV‐2 vaccination in single‐cell transcriptomics of recently allogeneic transplanted patients and healthy individuals.
29. High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group
30. Wichtige Differentialdiagnosen von Lungeninfiltraten bei hämatologischen Patienten
31. Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells
32. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse
33. Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma
34. Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation.
35. Malarial anemia: digestive vacuole of Plasmodium falciparum mediates complement deposition on bystander cells to provoke hemophagocytosis
36. Synchronous tuberculosis, Epstein-Barr virus-associated lymphoproliferative disorder and cytomegalovirus infection in an allogeneic transplant recipient: a case report
37. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
38. Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT.
39. In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors
40. Daratumumab for treatment‐refractory antibody‐mediated diseases in neurology.
41. Paired Donor and Recipient Immunophenotyping in Allogeneic Hematopoietic Stem Cell Transplantation: A Cellular Network Approach.
42. A Novel Method to Quantify and Characterize Leukemia-Reactive Natural Killer Cells in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation following Conventional or Reduced-Dose Conditioning
43. Results from a national survey on COVID‐19‐associated mucormycosis in Germany: 13 patients from six tertiary hospitals.
44. A novel sporadic Burkitt lymphoma cell line (BLUE-1) with a unique t(6;20)(q15;q11.2) rearrangement
45. Expression of interleukin 15 in primary adult acute lymphoblastic leukemia
46. Sensitivity of Tumor Cells to Proteasome Inhibitors Is Associated With Expression Levels and Composition of Proteasome Subunits
47. Cost-Benefit Assessment of Antifungal Prophylaxis with Liposomal Amphotericin B in Neutropenic Patients
48. Hemosiderin deposits in chronic graft-vs.-host disease related myopathy
49. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease
50. CD4+ T Cell Dependent B Cell Recovery and Function After Autologous Hematopoietic Stem Cell Transplantation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.